Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 72808 record(s)

Req # A-2023-000834

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-105345-217.

Organization: Health Canada

4 page(s)
April 2024

Req # A-2023-001018

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-107751-725.

Organization: Health Canada

8 page(s)
April 2024

Req # A-2023-001019

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-107996-10.

Organization: Health Canada

8 page(s)
April 2024

Req # A-2023-001197

Adverse Drug Reactions (ADRs) for Patiromer. Report numbers: E2B_06597912, E2B_06621747,E2B_06621748, E2B_06635757, E2B_06649755, E2B_06686722, E2B_06709717. ADRs for Brexpiprazole. Report numbers: E2B_06679153, E2B_06690064. ADR for Rexulti and…

Organization: Health Canada

117 page(s)
April 2024

Req # A-2023-001199

Adverse Drug Reactions (ADRs) for Tavneos. Report numbers: E2B_06591082, E2B_06617481, E2B_06623216, E2B_06634823, E2B_06639043, E2B_06641713, E2B_06672043, E2B_06685595, E2B_06691805. ADR for . Report number: 001055046.

Organization: Health Canada

64 page(s)
April 2024

Req # A-2023-001205

Adverse Drug Reactions (ADRs) for Ondansetron. Report numbers: E2B_06666868, E2B_06659902, E2B_06697588, E2B_06702227, E2B_06662559,E2B_06707974. ADR for Dexilant. Report number: 001069005. ADR for Entyvio. Report number: E2B_06698466. ADR for…

Organization: Health Canada

1174 page(s)
April 2024

Req # A-2023-001232

Adverse Drug Reactions (ADRs). Report numbers: 001063643, E2B_06694721, E2B_06676239.

Organization: Health Canada

2079 page(s)
April 2024

Req # A-2023-001247

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-110762-550.

Organization: Health Canada

5 page(s)
April 2024

Req # A-2023-001250

Adverse Drug Reactions (ADRs). Report numbers: 001038521, 001041193, E2B_06401905, 001038909, E2B_06356700, E2B_06336965, 001037598.

Organization: Health Canada

71 page(s)
April 2024

Req # A-2023-001304

Adverse Drug Reaction (ADR). Report number: E2B_06659476.

Organization: Health Canada

8 page(s)
April 2024
Date modified: